Status:
UNKNOWN
Pharmacokinetics of Sugammadex for the Reversal of Moderate Neuromuscular Blockade in Patients During Renal Transplantation
Lead Sponsor:
Guangzhou General Hospital of Guangzhou Military Command
Collaborating Sponsors:
Guangdong Provincial Hospital of Traditional Chinese Medicine
Conditions:
Pharmacokinetics
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to illustrate pharmacokinetics of sugammadex in reversal of rocuronium-induced moderate neuromuscular blockade in patients during renal transplantation
Detailed Description
34 patients undergoing renal transplantation or elective surgery are divided into 2 groups, including transplantation group (S group,n=17) and control group (C group, n=17). Patients age 18 to 65 and ...
Eligibility Criteria
Inclusion
- Patients undergo emergency renal transplantation under general anesthesia(CLCR≤30ml/min),or patients undergo elective surgery in supine position(CLCR≥80ml/min)
- Patients age 18 to 65
- ASA glass I-III
Exclusion
- patients suffering obstructive sleep apnea hypopnea syndrome or BMI≥28kg/m2
- Pregnant or lactating women
- neuromuscular disorders, hepatic dysfunction, cardiac disease, a history of malignant hyperthermia, or
- allergic history during general anesthesia
- patients receiving aminoglycoside antibiotics, anticonvulsants, magnesium,fusidic acid,toremifene and/or flucloxacillin
Key Trial Info
Start Date :
January 5 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2022
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT05187455
Start Date
January 5 2022
End Date
November 30 2022
Last Update
February 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangdong Hospital of Traditional Chinese Medicine
Guanzhou, Guangdong, China, 020